Manufacturers To Record Pearl Powder Purchases For SFDA Monitoring
This article was originally published in PharmAsia News
In response to a recent fake pearl powder incident, China's State FDA announced Sept. 25 that all manufacturers whose products contain pearl powder as an ingredient are required to establish records of their pearl powder purchases and a list of suppliers to make possible tracing of problematic pearl powder
You may also be interested in...
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.